Critical Survey: Immunocore (NASDAQ:IMCR) & TCR2 Therapeutics (NASDAQ:TCRR)

Immunocore (NASDAQ:IMCR – Get Rating) and TCR2 Therapeutics (NASDAQ:TCRR – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Institutional & Insider Ownership

65.1% of Immunocore shares are held by institutional investors. Comparatively, 64.8% of TCR2 Therapeutics shares are held by institutional investors. 5.7% of Immunocore shares are held by company insiders. Comparatively, 25.0% of TCR2 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Immunocore and TCR2 Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunocore	-25.53%	-16.63%	-10.47%
TCR2 Therapeutics	N/A	-97.81%	-69.35%

Volatility and Risk

Immunocore has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, TCR2 Therapeutics has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500.

Valuation & Earnings

This table compares Immunocore and TCR2 Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$165.80 million	15.02	-$50.99 million	($1.09)	-51.97
TCR2 Therapeutics	N/A	N/A	-$151.82 million	($4.20)	-0.45

Immunocore has higher revenue and earnings than TCR2 Therapeutics. Immunocore is trading at a lower price-to-earnings ratio than TCR2 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Immunocore and TCR2 Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	0	0	13	0	3.00
TCR2 Therapeutics	0	6	2	0	2.25

Immunocore currently has a consensus price target of $72.75, indicating a potential upside of 28.42%. TCR2 Therapeutics has a consensus price target of $4.91, indicating a potential upside of 161.40%. Given TCR2 Therapeutics’ higher possible upside, analysts plainly believe TCR2 Therapeutics is more favorable than Immunocore.

Summary

Immunocore beats TCR2 Therapeutics on 8 of the 13 factors compared between the two stocks.

About Immunocore

(Get Rating)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

About TCR2 Therapeutics

(Get Rating)

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.